Leveraging the Lysosome to Treat Glioblastoma

Time: 2:40 pm
day: Day Two

Details:

  • BXQ-350 – a unique, first in class, lysosomal protein (in lipid nanovesicle) involved in cellular homeostasis
  • Phase 1 clinical trial findings of extraordinary safety and tolerability with monotherapy effect
  • Planned clinical trials in newly diagnosed GBM – combination therapy
    with radiation and temozolomide

Speakers: